Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer - PubMed
6 hours ago
- #clinical study
- #therapy comparison
- #prostate cancer
- Comparison of triplet versus doublet therapy in metastatic hormone-sensitive prostate cancer.
- Study approved by Kyoto Prefectural University of Medicine's Institutional Review Boards (ERB-C-1071-2).
- Retrospective study design waived the need for written informed consent; opt-out information provided.
- Key drugs mentioned: Abiraterone acetate, Apalutamide, Darolutamide, Docetaxel, Enzalutamide.
- References include NCCN Guidelines and studies on Abiraterone, Enzalutamide, and Apalutamide efficacy.